Amifampridine
Approved · EMAAlso known as DAP, Firdapse, 3,4 DIAMINOPYRIDINE, 3,4-DAP+3 more
DAP, Firdapse, 3,4 DIAMINOPYRIDINE, 3,4-DAP, 3,4-Diaminopyridine, 3,4-Pyridinediamine, 4,5-Diaminopyridine.
Recent clinical, regulatory, research and industry developments relating to this drug.
Pilot Study on the Usefulness of 3,4-diaminopyridine in the Treatment of Botulism
Approval: Firdapse (previously Zenas) (EMA)
Fatigue in Multiple Sclerosis: Evaluated With 3 Tesla MRI and Transcranial Magnetic Stimulation
Randomized Study of 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Regulatory timeline
The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.
Indication: Symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults.
Evidence ↗Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Recent completions
Trials that read out recently, adding to the completed evidence base.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- ClinicalTrials.gov — clinical trials
- Regulatory event sources are credited in the Regulatory Timeline above.